Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?


Creative Commons License

Akay O. M., MUTLU F., Gulbas Z.

TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.2, pp.127-130, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.4274/tjh.2014.0213
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.127-130
  • Keywords: Platelet aggregation, Chronic myeloid leukemia, Imatinib mesylate, TYROSINE KINASE INHIBITOR, MYELOPROLIFERATIVE DISORDERS, C-KIT, AGGREGATION, RISTOCETIN, THROMBOSIS, MECHANISM, GROWTH, CELLS
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients.